ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY

BACKGROUND: TMZ offers minimal benefit in pts with de novo uMGMT GBM. V is synergistic with RT and TMZ in uMGMT preclinical GBM models, safe when combined with either RT or TMZ clinically, but the triplet (V+RT+TMZ) is poorly tolerated. VERTU tested V in pts with uMGMT GBM. METHODS: VERTU is a rando...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Khasraw, Mustafa, Leanne McDonald, Kerrie, Rosenthal, Mark, Lwin, Zarnie, Ashley, David, Wheeler, Helen, Barnes, Elizabeth, Foote, Matthew, Koh, Eng-Siew, Sulman, Erik, Back, Michael, Buckland, Michael, Sim, Hao-Wen, Fisher, Lauren, Leonard, Robyn, Hall, Merryn, Yip, Sonia, Simes, John
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Adult Clinical Trials - Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846916/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.067
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars